Molecular Markers and Prior Treatment Inform Maintenance PARP Inhibition in Ovarian Cancer
Homologous recombination deficiency (HRD) status, BRCA mutational status, and prior bevacizumab (Avastin) treatment should be used to inform which PARP inhibitor—olaparib (Lynparza), rucaparib (Rubraca), or niraparib (Zejula)—a patient with ovarian cancer should receive in the frontline or recurrent maintenance settings
The sentence directly states how biomarker status directs maintenance PARP inhibitor selection in ovarian cancer, highlighting the clinical decision‑making process that the article discusses.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements